Press Room

Webinar - PRIME: A Knowledge-based Assessment Tool to Classify Pharmaceutical Processes

Start
Monday, May 11, 2020 - 16:00
End
Monday, May 11, 2020 - 17:00
Location: online
Webinar Drug Substance Pharmaceutical Processes | 四色AV

Speakers

Rui Loureiro -听Director, R&D Process Chemistry Development
Filipe Ata铆de - Senior Scientist, R&D Process Chemistry Development

The manufacturing of API is a long and complex process. The comparison between the different processes is not easy since the chemical structures vary and therefore the compounds physical properties also change.

In this webinar we will be presenting the tool we developed to be able to take advantage of 60 years of experience in developing API process. The use of this tool allows us to develop our clients' projects using a Development by Design approach and to better manage the expectations of different outputs at different lifecycle stages of the processes. This follows a structured approach which allows for a faster process development.

What can you learn from this webinar?

  • How we score processes
  • How the knowledge can be used to develop an API manufacturing by design
  • How we can speed-up the process development

Join this webinar where our speakers will share their views on this new tool that is able to accelerate the development process.

Also in the Press Room

See All

Lisbon, Portugal 鈥 四色AV, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company鈥檚 dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, 四色AV joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company鈥檚 broader sustainability strategy and reinforces its commitment to scientific excellence. 鈥淎t 四色AV, we believe in science and in best practices. And this clearly applies to our sustainability agenda.鈥, said Jean-Luc Herbeaux, CEO of 四色AV. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.鈥 四色AV will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company鈥檚 environmental, social, and ethical performance, well aligned with 四色AV鈥檚 sustainability ambitions.  四色AV remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

四色AV Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024